New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BSX;HUM;AGP;UNH;WCG;MDT;HS;WLP;MOH;CI;STJ;AET;CNC;CVH;HNT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
February 1, 2016
08:52 EDTAETAetna sees FY16 revenue $62B, consensus $62.73B
Subscribe for More Information
08:48 EDTAETAetna expects Individual Commercial Results expected to improve in 2016
The company reported Individual Commercial losses were 3%-4% in Q4.
08:41 EDTAETAetna says individual commercial unit still unprofitable
Subscribe for More Information
08:39 EDTAETAetnaexpects to grow Individual Medicare advantage by 10% in 2016
Subscribe for More Information
08:17 EDTCNCCenturion selected to provide correctional healthcare in Florida
Centene Corporation announced that Centurion of Florida, a JV between Centene and MHM Services, has reached a formal agreement to provide correctional healthcare services for the Florida Department of Corrections in Regions 1, 2 and 3. This agreement with Centurion is a result of the State undertaking negotiation of a gap contract due to early termination by its prior vendor. The initial term of Centurion's contract with the Department of Corrections runs through January 2018 when the Department anticipates completion of a formal procurement. However, the agreement also includes optional renewal periods if the formal procurement is not finalized in the anticipated timeframe. Centurion will provide comprehensive healthcare services to over 70,000 inmates housed at facilities throughout the three Regions.
08:09 EDTAETOptions expected to be active
Options expected to be active: GOOGL GOOG YHOO UPS KORS UPS BAX RCL CCL PFE AET D STR DWA CMG ABT SYK.
08:05 EDTMDTMedtronic acquires Bellco
Medtronic announced it acquired privately-held Bellco, a pioneer in hemodialysis treatment solutions. Bellco's portfolio bolsters Medtronic's legacy renal access business and will be a foundational component of the company's recently formed Renal Care Solutions business. The Bellco transaction is expected to meet Medtronic's long-term financial metrics for acquisitions. Medtronic expects the net impact from the transaction to be earnings neutral in FY16 and neutral to accretive to earnings thereafter.
06:04 EDTAETAetna reports Q4 Health Care business revenue $14.4B
Reports Q4 Group Insurance revenue $618.3M. Reports Q4 Large Case Pensions revenue $67.5M.
06:03 EDTAET, HUMAetna on track to close Humana transaction in 2H16
The company commented, "We continue to work diligently with the Department of Justice and state regulators toward final approval of our proposed acquisition of Humana, and we continue to advance our integration readiness plans. We have obtained seven of the necessary state approvals, and we believe we remain on track to close the transaction in the second half of 2016."
06:02 EDTAETAetna sees FY16 operating EPS of at least $7.75, consensus $8.05
06:01 EDTAETAetna reports medical membership totaled 23.5M at December 31, 2015
Subscribe for More Information
06:01 EDTAETAetna reports Q4 operating EPS $1.37, consensus $1.21
Reports Q4 revenue $15.09B, consensus $14.93B.
January 29, 2016
16:25 EDTMDTMedtronic to present transcatheter pacing data to FDA
Subscribe for More Information
14:24 EDTCI, MOH, UNH, HUM, AETEarnings Watch: Aetna down 9% since last report
Aetna (AET) is scheduled to report fourth quarter earnings before the market open on Monday, February 1, with a conference call scheduled for 8:30 am ET. Aetna, a diversified health care benefits company in the United States, operates in three segments: Health Care, Group Insurance, and Large Case Pensions. EXPECTATIONS: Analysts are looking for earnings per share of $1.21 on revenue of $14.93B, according to First Call. The consensus range for EPS is $1.16-$1.32 on revenue of $14.44B-$15.36B. LAST QUARTER: Aetna reported third quarter EPS of $1.90 on revenue of $14.97B against analyst estimates of $1.77 and $14.95B, respectively. The company raised its fiscal 2015 EPS view to $7.45-$7.55 from "at least $7.40." Operating earnings were $668.6M for Q315 compared with $638.6M for Q314. The increase in operating earnings was primarily due to higher underwriting margins in Aetna's Health Care segment, partially offset by an increase in general and administrative expenses and lower underwriting margins in Aetna's Group Insurance segment. On January 11, Aetna said it see FY15 EPS at the high end of the $7.45-$7.55 range. Consensus for FY15 EPS is $7.54. STREET RESEARCH: On January 15, Wells Fargo said it expects health insurers' stock to do well this year, as the firm expects M&A deals made the last years to increase profits this year, and it thinks investors should be attracted to what it sees as the defensive names in the sector. Wells does not believe that any changes to or replacements of the ACA will be worse for the sector than the status quo. It identified Aetna and HCA Holdings (HCA) as its favorite names in the sector. On January 25, Leerink analyst Ana Gupte said she believed the recent selloff has provided a "strong" buying opportunity in the Managed Care space. Valuations are attractive on multiple metrics, Gupte told investors in a research note. Her top picks are UnitedHealth (UNH), Aetna, Humana (HUM) and Molina Healthcare (MOH). The analyst also favors Anthem (ANTM) and Cigna (CI). PRICE ACTION: Shares of Aetna are down approximately 9% since its last earnings report. The stock is up 2.6% to $101.42 in Friday afternoon trading ahead of Monday morning's report.
13:10 EDTAETAetna technical comments ahead of earnings
Subscribe for More Information
07:03 EDTAETAetna volatility elevated into Q4 and outlook
Aetna February weekly call option implied volatility is at 47, February and March is at 38; compared to its 52-week range of 18 to 44, suggesting large near term price movement into the expected release of Q4 results on February 1.
January 28, 2016
17:01 EDTAETAetna enters four-year reinsurance arrangement with Vitality Re VII
Aetna announced it has entered into a four-year reinsurance arrangement with Vitality Re VII. The arrangement allows Aetna to reduce its required capital and provides $200M of collateralized excess of loss reinsurance coverage on a portion of Aetna's group commercial health insurance business.
11:11 EDTSTJHeartWare rallies after scrapping Valtech acquisition
The shares of HeartWare (HTWR) are surging after the company announced that would terminate its acquisition of privately held Valtech. Two research firms reacted positively to the news, with Leerink Swann saying that the company made the right decision, given its current difficulties and Raymond James upgrading HeartWare following the news. HeartWare develops and manufactures miniaturized implantable heart pumps, while Valtech has developed a method of replacing mitral valves in human hearts without the need for open heart surgery. WHAT'S NEW: HeartWare decided to terminate its acquisition of Valtech, the companies announced this morning. Pursuant to the terms of the agreement, HeartWare will make a $30M loan to Valtech in the form of a convertible promissory note. ANALYST REACTION: HeartWare's decision to abandon its acquisition of Valtech was correct in light of the problems that the company is facing with its next generation MVAD pump, Leerink analyst Danielle Antalffy wrote in a note to investors today. Noting that two weeks ago HeartWare announced that it would investigate suction issues that the device has had, the analyst says that fixing the pump could require additional investment, while it's uncertain how long it will take to solve the device's problems. However, the analyst remained upbeat on Heartware's current LVAD products, and believes that it can compete with next generation systems. She kept a $60 price target and Outperform rating on the shares. Raymond James upgraded HeartWare to Outperform from Market Perform, saying that the termination of the Valtech deal removes an overhang on the shares, while the stock's underperformance since September has made its valuation more attractive. Moreover, the stock does not appear to be giving any value to the problematic MVAD pump and the company has a 37% share of a $760M market that has only two main competitors and high barriers to entry, the firm wrote. WHAT'S NOTABLE: In early October 2015, activist investor Engaged Capital urged HeartWare to terminate the Valtech deal. Today HeartWare announced that it would, in conjunction with Engaged Capital, "jointly select" an independent party who will join Heartware's board. ANOTHER TO WATCH: HeartWare's chief rival, Thoratec, was acquired last year by St. Jude Medical (STJ). PRICE ACTION: In late morning trading, HeartWare rose 10% to $37.95. St. Jude, which reported its fourth quarter results and gave fiscal year guidance this morning, is down 1.4% to $53.56.
07:14 EDTBSXBoston Scientific and Accenture develop digital health solution
Subscribe for More Information
06:24 EDTUNHAnthem added to Focus List at Citi
Citi analyst Ralph Giacobbe added Anthem (ANTM) to his firm's Focus List. As Anthem and Express Scripts (ESRX) continue to negotiate their pharmacy benefits manager contract, the analyst sees UnitedHealth (UNH) as a potential alternative for Anthem. Regardless of the outcome, Anthem is in the "driver's seat for significant savings/upside," which is not reflected in the stock. Giacobbe tells investors in a research note. He keeps a Buy rating on the name with a $172 price target.
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use